Dr. Udit Verma on Managing Regorafenib Side Effects in CRC

Udit Verma, MD
Published: Thursday, Jul 21, 2016


Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses managing the side effects of regorafenib in patients with metastatic colorectal cancer (mCRC).
 
The standard recommended dose of regorafenib is 160 mg dose per day on a three weeks on, one week off cycle.
 
Hand-foot-skin reaction is the side effect that requires the most management, says Verma. Reducing the dose to 120 mg may make the reaction less severe. The drug may also need to be delayed for several days.
 
Hand-foot-skin reaction rapidly improves, so if a patient has a reaction that is grade 3 or more, an oncologist can hold off the dose until it is grade 1 and then start it up again at 120 mg per day.  
 
If there are still problems, the dose can be further reduced to 80 mg per day, says Verma.

Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses managing the side effects of regorafenib in patients with metastatic colorectal cancer (mCRC).
 
The standard recommended dose of regorafenib is 160 mg dose per day on a three weeks on, one week off cycle.
 
Hand-foot-skin reaction is the side effect that requires the most management, says Verma. Reducing the dose to 120 mg may make the reaction less severe. The drug may also need to be delayed for several days.
 
Hand-foot-skin reaction rapidly improves, so if a patient has a reaction that is grade 3 or more, an oncologist can hold off the dose until it is grade 1 and then start it up again at 120 mg per day.  
 
If there are still problems, the dose can be further reduced to 80 mg per day, says Verma.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x